secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2026-09-30T21:27:25+00:00
Accession:  0001140361-26-038110
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 1.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Standard BioTools to sell mass cytometry business to Element Biosystems for $5.5M after terminating Multiplex Bio deal
--------------------------------------------------------------------------------

- Standard BioTools terminated its July 28, 2026 agreement to sell the mass cytometry business to Multiplex Bio and paid a $1.5 million termination fee.
- On September 30, 2026, the company signed a Share and Asset Purchase Agreement with Element Biosystems, a GMT Venture subsidiary, for $5.5 million cash on a cash-free, debt-free basis.
- GMT Venture agreed to pay $1.0 million toward the Multiplex termination fee and provided an equity commitment letter to fund Element's obligations; no financing condition applies.
- The Element deal requires Standard BioTools stockholder approval and consummation of its pending merger with Treeline Biosciences; closing is expected by end of 2026.
- The company says the Element deal improves net cash for the Treeline exchange ratio by about $15 million versus Multiplex; on specified termination, Standard BioTools owes Element $1.0 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000114036126038110/0001140361-26-038110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000114036126038110/ef20082995_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-038110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer